Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 6Solid Tumor 3Neoplasms 3Advanced Solid Tumors 3Stomach Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Advanced Solid Tumor 2Advanced Lung Cancer 2Uterine Cervical Neoplasms 1Squamous NSCLC 1SCLC 1Ovarian Neoplasms 1Osteosarcoma 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Melanoma 1MSI-H 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Gastrointestinal Diseases 1Esophageal Diseases 1Carcinoma, Squamous Cell 1Advanced/Metastatic Solid Malignancies 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumours 1

Interventions

pembrolizumab 4envafolimab 3Nivolumab 3Injections 2trifluridine tipiracil drug combination 1tebentafusp 1surufatinib 1sintilimab 1linifanib 1cobimetinib 1TAK-981 1Ipilimumab 1Doxorubicin 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced or Metastatic Solid Tumors × sintilimab × Clear all
NCT04427774 2021-07-20

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
8 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡